CD4+ Treg lymphocyte subsets, often present in the tumor, promote EMT by secreting IL-10 and TGF-β, which activate signaling pathways supporting the loss of epithelial features and acquisition of a mesenchymal phenotype by tumor cells. Here, TGFB1 is linked to neoplasm.